Latest Allotransplantation Stories
KENNESAW, Ga., Feb. 11, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of four new issued patents related to tissue grafts derived from the placenta. The U.S. Patent Office has issued to MiMedx U.S. Patent Number 8,357,403, "Placental Tissue Grafts," with a grant date of January 22, 2013. The U.S...
DENVER, Feb. 5, 2013 /PRNewswire/ -- Donor Alliance, the federally-designated, non-profit organ procurement organization and American Association of Tissue Banks (AATB) accredited tissue bank serving Colorado and Wyoming, recorded another impactful year in 2012, helping save the lives of nearly 400 people through organ donation and transplantation. In addition, the organization worked with over one thousand tissue donors and their families to recover lifesaving and healing tissue...
The gift of donation lives on by advancing the science of medicine CENTENNIAL, Colo., Jan. 29, 2013 /PRNewswire-USNewswire/ -- AlloSource, one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures and the world's largest processor of cellular bone allografts, today announced the donation of research tissue to the Steadman Philippon Research Institute (SPRI) in order to further honor the gift of tissue donation. "The...
HORSHOLM, Denmark, Jan. 3, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S today is announcing that the LCP-Tacro Phase III clinical trial in stable kidney transplant patients, the 3001 study, has been published online in the American Journal of Transplantation. The article reports on the randomized, controlled, multicenter Phase III trial, which demonstrated that LCP-Tacro dosed once-daily was not inferior to the current leading transplant drug, Prograf(®), dosed twice-daily....
A combination of three blood-borne proteins may bolster efforts to prevent graft loss years after transplant BOSTON, Dec. 26, 2012 /PRNewswire-USNewswire/ -- Researchers at Boston Children's Hospital have found a combination of biomarkers related to blood vessel and tissue injury that, when measured together, could signal when a transplanted heart is becoming damaged to the point of failure, a process that is often undetected. The markers would give doctors an opportunity to...
Joe Gutierrez participates in the 2013 Tournament of Roses Parade® showing the country the life-changing impact of tissue donation CENTENNIAL, Colo., Dec. 19, 2012 /PRNewswire-USNewswire/ -- AlloSource, one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures and the world's largest processor of cellular bone allografts, announces its seventh annual sponsorship of a tissue recipient float rider aboard the annual Donate...
KENNESAW, Ga., Dec. 6, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of the Company's first issued patent related to tissue grafts derived from the placenta. The U.S. Patent Office has issued to MiMedx U.S. Patent Number 8,323,701, "Placental Tissue Grafts", originally filed in...
DENVER, Nov. 26, 2012 /PRNewswire/ -- For the first time, Colorado and Wyoming families of organ, eye and tissue donors, transplant recipients and living donors will escort a balloon float in the annual 9News Parade of Lights in downtown Denver Friday, November 30 and Saturday, December 1. The Donate Life Colorado float, titled "Gift of Life" will be a jumbo balloon in the shape of a gift box, representing the hope made possible by organ, eye and tissue donation. Donate Life...
NEW YORK, Nov. 15, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced today that it has been notified according to the FDA validation registration number 3009842420, that its new facility located at 460 Park Avenue, New York, NY 10022 is now registered to recover, process, package, store, and label human cells and tissue products (HCT/P's) such as the IntelliCell autologous stromal vascular fraction cellular product. The registration is required under...
NEW YORK, Nov. 9, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced today that it has been notified according to the FDA validation registration number 3009842420, that its new facility located at 460 Park Avenue, New York, NY 10022 is now registered to recover, process, package, store, and label human cells and tissue products (HCT/P's) such as the IntelliCell autologous stromal vascular fraction cellular product. In the registration notification,...
